EFFICIENT DESIGNS FOR RANDOMIZED TRIALS WITH RESPONSE AS AN END-POINT

被引:0
|
作者
WIEAND, S [1 ]
THERNEAU, T [1 ]
机构
[1] MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905
来源
CONTROLLED CLINICAL TRIALS | 1986年 / 7卷 / 03期
关键词
D O I
10.1016/0197-2456(86)90077-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
引用
收藏
页码:236 / 236
页数:1
相关论文
共 50 条
  • [1] Exercise as an end-point in pulmonary hypertension trials
    McCullagh, B.
    Girgis, R. E.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2010, 64 : 4 - 6
  • [2] End-Point Selection for Acute Heart Failure Trials
    Allen, Larry A.
    HEART FAILURE CLINICS, 2011, 7 (04) : 481 - +
  • [3] CHEMOPREVENTION TRIALS AND SURROGATE END-POINT BIOMARKERS IN THE CERVIX
    MITCHELL, MF
    HITTELMAN, WK
    LOTAN, R
    NISHIOKA, K
    TORTOLEROLUNA, G
    RICHARDSKORTUM, R
    WHARTON, JT
    HONG, WK
    CANCER, 1995, 76 (10) : 1956 - 1977
  • [4] End-point interpretation in clinical trials:: The case for discipline
    Moyé, LA
    CONTROLLED CLINICAL TRIALS, 1999, 20 (01): : 40 - 49
  • [6] Protein C as a surrogate end-point for clinical trials of sepsis
    Liu, Kathleen D.
    Matthay, Michael A.
    CRITICAL CARE, 2008, 12 (02):
  • [7] SURROGATE END-POINT USE IN CARDIOVASCULAR CLINICAL-TRIALS
    PROBSTFIELD, JL
    YUSUF, S
    FRIEDMAN, LM
    LABARTHE, DR
    BRISTOW, JD
    WITTES, J
    CONTROLLED CLINICAL TRIALS, 1986, 7 (03): : 241 - 242
  • [8] Innovation in pediatric clinical trials: The need to rethink the end-point
    Glass, Lauren
    Conway, Jennifer
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2018, 37 (04): : 431 - 432
  • [9] TISSUE AUTOFLUORESCENCE AS AN INTERMEDIATE END-POINT IN CANCER CHEMOPREVENTION TRIALS
    SCHANTZ, SP
    ALFANO, RR
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1993, : 199 - 204
  • [10] Protein C as a surrogate end-point for clinical trials of sepsis
    Kathleen D Liu
    Michael A Matthay
    Critical Care, 12